Skip to main content

ATRA

Stock
Health Care
Biotechnology

Performance overview

ATRA Price
Price Chart

Forward-looking statistics

Beta
2.24
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Company info

SectorHealth Care
IndustryBiotechnology
Employees363
Market cap$63.7M

Fundamentals

Enterprise value$74.1M
Revenue$199.7M
Revenue per employee—
Profit margin-7.83%
Debt to equity-0.76

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.26
Dividend per share—
Revenue per share$22.77
Avg trading volume (30 day)$457K
Avg trading volume (10 day)$263K
Put-call ratio—

Macro factor sensitivity

Growth-0.1
Credit+13.3
Liquidity-1.4
Inflation-5.2
Commodities-1.9
Interest Rates-4.3

Valuation

Dividend yield0.00%
PEG Ratio-0.97
Price to sales0.29
P/E Ratio-0.97
Enterprise Value to Revenue0.37
Price to book-1.65

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day—
Ex. dividend day—

News

Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade

Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (March 13, 2025)
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.'s ATRA active Investigational New Drug (IND) applications.

Benzinga (January 21, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free